Ocumension Therapeutics’ NDA accepted by China’s NMPA
Ocumension Therapeutics said the NMPA accepted its NDA for OT-301, also described as NCX 470 with bimatoprost genod.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.